Fluidigm Corporation today announced that due to the historic instability in the market, the company is withdrawing its registration statement for its initial public offering of shares of common stock.
“We went out on September 5th with a very strong story and Fluidigm received a warm reception from the investment community. We explained how our technology contributed to life science research and how the company was poised to grow,” said Gajus Worthington, Fluidigm President and Chief Executive Officer. “While these messages were well-received, pushing ahead with a deal in the current market was not in our best interest. We have decided to withdraw our S-1 statement rather than keep it pending. By doing so, we free ourselves of the communication restrictions that an active registration statement imposes.”
Fluidigm develops, manufactures and markets proprietary Integrated Fluidic Circuit (IFC) systems that significantly improve productivity in life science research. Fluidigm’s IFCs enable the simultaneous performance of thousands of sophisticated biochemical measurements in extremely minute volumes. These “integrated circuits for biology” are made possible by miniaturizing and integrating liquid handling components on a single microfabricated device. Fluidigm’s IFC systems, consisting of instrumentation, software and single-use IFCs, increase throughput, decrease costs and enhance sensitivity compared to conventional laboratory systems. Fluidigm products have not been cleared or approved by the Food and Drug Administration for use as a diagnostic and are only available for research use.
For more information about the company, please visit www.Fluidigm.com.
Fluidigm, the Fluidigm logo, Topaz, BioMark, and NanoFlex are trademarks of Fluidigm Corporation.
Contacts:
Howard High, 650-266-6081 (office)
Mobile:
510-786-7378
